136 related articles for article (PubMed ID: 36992564)
1. Evaluation of sexual function after dutasteride treatment in patients with once-negative prostate biopsy and benign prostate hyperplasia.
Taniguchi H; Inoue T; Kawa G; Murota T; Tsukino H; Yoshimura K; Kamoto T; Ogawa O; Matsuda T; Kinoshita H
Urologia; 2023 May; 90(2):295-300. PubMed ID: 36992564
[TBL] [Abstract][Full Text] [Related]
2. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
Traish A; Haider KS; Doros G; Haider A
Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
[TBL] [Abstract][Full Text] [Related]
3. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
4. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
[TBL] [Abstract][Full Text] [Related]
6. Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes.
Enatsu N; Miyake H; Haraguchi T; Chiba K; Fujisawa M
Andrologia; 2016 Dec; 48(10):1195-1201. PubMed ID: 26952737
[TBL] [Abstract][Full Text] [Related]
7. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
8. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Lin VC; Liao CH; Wang CC; Kuo HC
J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
[TBL] [Abstract][Full Text] [Related]
9. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
10. A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride.
Maeda T; Kikuchi E; Hasegawa M; Ando T; Matsushima M; Yuge K; Ito Y; Miyajima A; Oya M
Aging Male; 2016 Jun; 19(2):111-6. PubMed ID: 26964647
[TBL] [Abstract][Full Text] [Related]
11. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
14. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
16. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
18. [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA].
Endo T; Kamiya N; Yano M; Oka R; Lee FC; Utsumi T; Kamijima S; Nishimi D; Takanami M; Hiruta N; Suzuki H
Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):156-62. PubMed ID: 26419072
[TBL] [Abstract][Full Text] [Related]
19. Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride.
Watanabe D; Yamashita A; Miura K; Mizushima A
Aging Male; 2020 Dec; 23(5):501-506. PubMed ID: 30457437
[TBL] [Abstract][Full Text] [Related]
20. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
